Mitigating Manufacturer Exposure to US MFN Policy

As US Most Favored Nation (MFN) drug pricing policy frameworks take shape, biopharmaceutical manufacturers face a new level of global pricing complexity.

First Name *

Last Name *

Company Name *

Email Address *

Job Title *

Country*

I have read and agree to the Foundry Privacy Policy which describes how my personal data may be used.

I consent for my personal data including my email address, phone number and firmographic information be used by Syneos Health for Marketing emails, phone calls, and offers and content from its partners, and transfer to Foundry’s affiliate locations available on the Contact Us page.

Would you like to receive information about promotional offers and relating products and services from Foundry and Syneos Health through a phone call or an email?

Thank You!

Your download will start momentarily,